Towards Understanding Aromatase Inhibitory Activity Via QSAR Modeling

Overview

Journal EXCLI J

Specialty Biology

Date 2018 Sep 8

PMID 30190660

Citations 12

Authors

Watshara Shoombuatong

Nalini Schaduangrat

Chanin Nantasenamat

Affiliations

Soon will be listed here.

Abstract

Aromatase is a rate-limiting enzyme for estrogen biosynthesis that is overproduced in breast cancer tissue. To block the growth of breast tumors, aromatase inhibitors (AIs) are employed to bind and inhibit aromatase in order to lower the amount of estrogen produced in the body. Although a number of synthetic aromatase inhibitors have been released for clinical use in the treatment of hormone-receptor positive breast cancer, these inhibitors may lead to undesirable side effects (e.g. increased rash, diarrhea and vomiting; effects on the bone, brain and heart) and therefore, the search for novel AIs continues. Over the past decades, there has been an intense effort in employing medicinal chemistry and quantitative structure-activity relationship (QSAR) to shed light on the mechanistic basis of aromatase inhibition. To the best of our knowledge, this article constitutes the first comprehensive review of all QSAR studies of both steroidal and non-steroidal AIs that have been published in the field. Herein, we summarize the experimental setup of these studies as well as summarizing the key features that are pertinent for robust aromatase inhibition.

Citing Articles

First report on chemometrics-driven multilayered lead prioritization in addressing oxysterol-mediated overexpression of G protein-coupled receptor 183.

Bhattacharjee A, Kar S, Ojha P Mol Divers. 2024; 28(6):4199-4220.

PMID: 38460065 DOI: 10.1007/s11030-024-10811-1.

Mpropred: A machine learning (ML) driven Web-App for bioactivity prediction of SARS-CoV-2 main protease (Mpro) antagonists.

Ferdous N, Reza M, Hossain M, Mahmud S, Napis S, Chowdhury K PLoS One. 2023; 18(6):e0287179.

PMID: 37352252 PMC: 10289339. DOI: 10.1371/journal.pone.0287179.

Towards combating antibiotic resistance by exploring the quantitative structure-activity relationship of NDM-1 inhibitors.

Yu T, Malik A, Anuwongcharoen N, Eiamphungporn W, Nantasenamat C, Piacham T EXCLI J. 2022; 21:1331-1351.

PMID: 36540675 PMC: 9755517. DOI: 10.17179/excli2022-5380.

SCORPION is a stacking-based ensemble learning framework for accurate prediction of phage virion proteins.

Ahmad S, Charoenkwan P, Quinn J, Moni M, Hasan M, Lio P Sci Rep. 2022; 12(1):4106.

PMID: 35260777 PMC: 8904530. DOI: 10.1038/s41598-022-08173-5.

Ensemble machine learning to evaluate the in vivo acute oral toxicity and in vitro human acetylcholinesterase inhibitory activity of organophosphates.

Wang L, Ding J, Shi P, Fu L, Pan L, Tian J Arch Toxicol. 2021; 95(7):2443-2457.

PMID: 33934188 DOI: 10.1007/s00204-021-03056-6.

References

Coombes R, Kilburn L, Snowdon C, Paridaens R, Coleman R, Jones S . Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007; 369(9561):559-70. DOI: 10.1016/S0140-6736(07)60200-1. View

Klebe G, Abraham U, Mietzner T . Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem. 1994; 37(24):4130-46. DOI: 10.1021/jm00050a010. View

Simpson E, Mahendroo M, Means G, Kilgore M, Hinshelwood M, Amarneh B . Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev. 1994; 15(3):342-55. DOI: 10.1210/edrv-15-3-342. View

Barigye S, Freitas M, Ausina P, Zancan P, Sola-Penna M, Castillo-Garit J . Discrete Fourier Transform-Based Multivariate Image Analysis: Application to Modeling of Aromatase Inhibitory Activity. ACS Comb Sci. 2018; 20(2):75-81. DOI: 10.1021/acscombsci.7b00155. View

Nelson L, Bulun S . Estrogen production and action. J Am Acad Dermatol. 2001; 45(3 Suppl):S116-24. DOI: 10.1067/mjd.2001.117432. View

Recanatini M . Comparative molecular field analysis of non-steroidal aromatase inhibitors related to fadrozole. J Comput Aided Mol Des. 1996; 10(1):74-82. DOI: 10.1007/BF00124467. View

Bonnefoi H, Smith I, Dowsett M, Trunet P, Houston S, da Luz R . Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer. Br J Cancer. 1996; 73(4):539-42. PMC: 2074462. DOI: 10.1038/bjc.1996.93. View

Girones X, Carbo-Dorca R . Molecular quantum similarity-based QSARs for binding affinities of several steroid sets. J Chem Inf Comput Sci. 2002; 42(5):1185-93. DOI: 10.1021/ci0202842. View

Roy P, Roy K . Docking and 3D-QSAR studies of diverse classes of human aromatase (CYP19) inhibitors. J Mol Model. 2010; 16(10):1597-616. DOI: 10.1007/s00894-010-0667-y. View

10.

Polanski J, Gieleciak R . The comparative molecular surface analysis (CoMSA) with modified uniformative variable elimination-PLS (UVE-PLS) method: application to the steroids binding the aromatase enzyme. J Chem Inf Comput Sci. 2003; 43(2):656-66. DOI: 10.1021/ci020038q. View

11.

Song Z, Liu Y, Dai Z, Liu W, Zhao K, Zhang T . Synthesis and aromatase inhibitory evaluation of 4-N-nitrophenyl substituted amino-4H-1,2,4-triazole derivatives. Bioorg Med Chem. 2016; 24(19):4723-4730. DOI: 10.1016/j.bmc.2016.08.014. View

12.

Lee S, Barron M . 3D-QSAR study of steroidal and azaheterocyclic human aromatase inhibitors using quantitative profile of protein-ligand interactions. J Cheminform. 2018; 10(1):2. PMC: 5773458. DOI: 10.1186/s13321-017-0253-8. View

13.

Simeon S, Anuwongcharoen N, Shoombuatong W, Malik A, Prachayasittikul V, Wikberg J . Probing the origins of human acetylcholinesterase inhibition via QSAR modeling and molecular docking. PeerJ. 2016; 4:e2322. PMC: 4991866. DOI: 10.7717/peerj.2322. View

14.

Pingaew R, Mandi P, Prachayasittikul V, Prachayasittikul S, Ruchirawat S, Prachayasittikul V . Synthesis, molecular docking, and QSAR study of sulfonamide-based indoles as aromatase inhibitors. Eur J Med Chem. 2017; 143:1604-1615. DOI: 10.1016/j.ejmech.2017.10.057. View

15.

Simeon S, Spjuth O, Lapins M, Nabu S, Anuwongcharoen N, Prachayasittikul V . Origin of aromatase inhibitory activity via proteochemometric modeling. PeerJ. 2016; 4:e1979. PMC: 4868594. DOI: 10.7717/peerj.1979. View

16.

Worachartcheewan A, Shoombuatong W, Pidetcha P, Nopnithipat W, Prachayasittikul V, Nantasenamat C . Predicting Metabolic Syndrome Using the Random Forest Method. ScientificWorldJournal. 2015; 2015:581501. PMC: 4531182. DOI: 10.1155/2015/581501. View

17.

Nantasenamat C, Li H, Mandi P, Worachartcheewan A, Monnor T, Isarankura-Na-Ayudhya C . Exploring the chemical space of aromatase inhibitors. Mol Divers. 2013; 17(4):661-77. DOI: 10.1007/s11030-013-9462-x. View

18.

Beger R, Buzatu D, Wilkes J, Lay Jr J . (13)C NMR quantitative spectrometric data-activity relationship (QSDAR) models of steroids binding the aromatase enzyme. J Chem Inf Comput Sci. 2001; 41(5):1360-6. DOI: 10.1021/ci010285e. View

19.

Santen R, SAMOJLIK E, Wells S . Resistance of the ovary to blockade of aromatization with aminoglutethimide. J Clin Endocrinol Metab. 1980; 51(3):473-7. DOI: 10.1210/jcem-51-3-473. View

20.

Bak A, Polanski J . Modeling robust QSAR 3: SOM-4D-QSAR with iterative variable elimination IVE-PLS: application to steroid, azo dye, and benzoic acid series. J Chem Inf Model. 2007; 47(4):1469-80. DOI: 10.1021/ci700025m. View